Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B

被引:74
作者
Gray, Elin Solomonovna
Meyers, Tammy
Gray, Glenda
Montefiori, David Charles
Morris, Lynn [1 ]
机构
[1] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa
[2] Univ Witwatersrand, Harriet Shezi Clin, Johannesburg, South Africa
[3] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pmed.0030255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A Phase I clinical trial has been proposed that uses neutralising monoclonal antibodies (MAbs) as passive immunoprophylaxis to prevent mother-to-child transmission of HIV-1 in South Africa. To assess the suitability of such an approach, we determined the sensitivity of paediatric HIV-1 subtype C viruses to the broadly neutralising MAbs IgG1b12, 2G12, 2F5, and 4E10. Methods and Findings: The gp160 envelope genes from seven children with HIV-1 subtype C infection were cloned and used to construct Env-pseudotyped viruses that were tested in a single-cycle neutralisation assay. The epitopes defining three of these MAbs were determined from sequence analysis of the envelope genes. None of the seven HIV-1 subtype C pseudovirions was sensitive to 2G12 or 2F5, which correlated with the absence of crucial N-linked glycans that define the 2G12 epitope and substitutions of residues integral to the 2F5 epitope. Four viruses were sensitive to IgG1b12, and all seven viruses were sensitive to 4E10. Conclusions: Only 4E10 showed significant activity against HIV-1 subtype C isolates, while 2G12 and 2F5 MAbs were ineffective and IgG1b12 was partly effective. It is therefore recommended that 2G12 and 2F5 MAbs not be used for passive immunization experiments in southern Africa and other regions where HIV-1 subtype C viruses predominate.
引用
收藏
页码:1023 / 1031
页数:9
相关论文
共 57 条
[1]  
[Anonymous], 2003, NAT HIV SYPH ANT SER
[2]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[3]   MOLECULAR PROFILE OF AN ANTIBODY-RESPONSE TO HIV-1 AS PROBED BY COMBINATORIAL LIBRARIES [J].
BARBAS, CF ;
COLLET, TA ;
AMBERG, W ;
ROBEN, P ;
BINLEY, JM ;
HOEKSTRA, D ;
CABABA, D ;
JONES, TM ;
WILLIAMSON, RA ;
PILKINGTON, GR ;
HAIGWOOD, NL ;
CABEZAS, E ;
SATTERTHWAIT, AC ;
SANZ, I ;
BURTON, DR .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 230 (03) :812-823
[4]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[5]   SYNERGY BETWEEN HUMAN MONOCLONAL-ANTIBODIES TO HIV EXTENDS THEIR EFFECTIVE BIOLOGIC ACTIVITY AGAINST HOMOLOGOUS AND DIVERGENT STRAINS [J].
BUCHBINDER, A ;
ZOLLAPAZNER, S ;
KARWOWSKA, S ;
GORNY, MK ;
BURDA, ST .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (08) :1395-1395
[6]   Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa [J].
Bures, R ;
Morris, L ;
Williamson, C ;
Ramjee, G ;
Deers, M ;
Fiscus, SA ;
Abdool Karim, SS ;
Montefiori, DC .
JOURNAL OF VIROLOGY, 2002, 76 (05) :2233-2244
[7]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[8]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[9]   A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS [J].
BURTON, DR ;
BARBAS, CF ;
PERSSON, MAA ;
KOENIG, S ;
CHANOCK, RM ;
LERNER, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10134-10137
[10]   Antibody domain exchange is an immunological solution to carbohydrate cluster recognition [J].
Calarese, DA ;
Scanlan, CN ;
Zwick, MB ;
Deechongkit, S ;
Mimura, Y ;
Kunert, R ;
Zhu, P ;
Wormald, MR ;
Stanfield, RL ;
Roux, KH ;
Kelly, JW ;
Rudd, PM ;
Dwek, RA ;
Katinger, H ;
Burton, DR ;
Wilson, IA .
SCIENCE, 2003, 300 (5628) :2065-2071